ThromboGenics (THR)

Business description

ThromboGenics is a Belgian biopharmaceutical company focused on developing and commercialising the eye drug ocriplasmin; EU (via Alcon) and US launches are due in Q113. Antibody candidates targeting cardiovascular disorders and cancer are in mid-stage clinical trials.

All eyes on Jetrea launch

QuickView | Pharmaceutical & healthcare | 25/10/2012

Jetrea’s US approval is a significant milestone for ThromboGenics and its recent share price performance reflects this. With a first-pass FDA endorsement in the broadest possible indication and EU approval due in Q113, shares are trading at c 3% off an all-time high. Investor interest should now turn to the US launch, due in January 2013. Jetrea’s pricing could, however, offer near-term upside, with suggestions that prior guidance could be overly conservative.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.